TAVI

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

Coronary Calcification: More Frequent Use of Coronary Lithotripsy as a Recommendation

Coronary calcification, whether concentric or eccentric, has always posed a challenge in percutaneous coronary intervention (PCI) due to difficulties in plaque preparation, device navigability, proper stent apposition, drug release, and potential complications during the procedure. This study analyzed 262 patients who participated in the four Disrupt CAD OCT Studies and underwent PCI using coronary lithotripsy followed...

TCT 2023 | ALIGN AR trial

TCT 2023 The LIFE-BTK Trial

This was a randomized study including 261 patients treated with infrapatellar percutaneous transluminal angioplasty.173 of these patients received an everolimus bioresorbable scaffold while the remaining 88 were treated with balloon angioplasty.  The efficacy primary end point was limb salvage and primary patency rates at 12 months and the safety primary end point was freedom from...

TCT 2023 | ALIGN AR trial

TCT 2023 | COMPARE 60/80 HBR TRIAL

This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT).  A total 747 patients were recruited, 368 received PCI with the ultrathin Superflex stent with 60 µm struts (SUF), and 364 received the Terumo Tansei with 89 µm struts (SF). Primary end point was NACE at...

TCT 2023 | ALIGN AR trial

TCT 2023 | In Stent Restenosis: Sirolimus vs. Paclitaxel Coated Balloons

This was a prospective, multicenter, randomized study including 130 patients with instent restenosis treated with sirolimus coated balloons (DCB S) and 128 treated with paclitaxel coated balloons (DCB P).  Primary end point was late lumen loss (LLL) at 12 months.  There were no significant differences between the groups. Mean patient age was 63, 75% were...

TCT 2023 | ALIGN AR trial

TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome

This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one month (1,426 patients), followed by ticagrelor monotherapy for 12 months, while the other group received DAPT with ASA and ticagrelor during 12 months (1,424 patients). This study was...

TCT 2023 | ALIGN AR trial

TCT 2023 | SWEDEHEART, Evolution at 5 Years

This register included 42,887 patients receiving FFR or iFR to assess moderate lesions, and 80% of them underwent FFR. Population characteristics were similar, except that the iFR group had more women, with more diabetes, MI, stroke and chronic obstructive pulmonary disease (COPD). Primary end point was a composite of all cause death, MI and unplanned...

OBSERVANT II: Post TAVR 30-Day and 6-Month Stroke Predictors

Despite stroke rate has declined since the early days of transcatheter aortic valve replacement (TAVR), it remains significant, reaching 1% to 3% 30 days after procedure. Since TAVR has seen a progressive expansion to the low risk and young populations, identifying risk factors in patient selection and management is crucial for us to prevent stroke. ...

Resultados del estudio COMPARE a 2 años: Balones cubiertos de Paclitaxel con bajas dosis vs altas dosis

Ultrathin Stents Shown Safe and Effective in Real World Patients

Ultrathin drug eluting stents (60 µm) had been shown beneficial vs. thin-strut stents in terms of target lesion failure (TLF) at 2, 3 and 5 years in randomized studies, but they had not been yet assessed in “real world” patients.  The BIOFLOW VII is a prospective, multicenter study including 556 “real world”patients with a total...

Sedación consciente vs anestesia general en el TAVI

Cause of Cardiac Death after TAVR at Present

Cardiac failure (CF) and sudden cardiac death (SCD) stand out as two of the main causes of death in patients with aortic stenosis. Although transcatheter aortic valve intervention has shown higher survival, these two continue to be the main conditions leading to patient death at followup.  In its early days, TAVR also showed benefits, but...

Top